Results for this period
Interim period (second quarter)1 April 2026 to 30 September 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit.
The shaded area represents net assets as a proportion of total assets. It is calculated from the two amounts reported by the company.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ thousand).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
In the Drug Discovery Support business, progress in contract testing and cost reductions through the streamlining of operations; in the Investment and Consulting business, improvements in the e-commerce market environment, completion of large-scale orders, demand capture, price pass-through and cost control.
Not applicable.
| Item | Details |
|---|---|
| Fiscal Period Classification | Interim period (second quarter) |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2026 to 30 September 2026 |
| Net Sales | ¥7,069,846 thousand (YoY +13.6%) |
| Operating profit | ¥161,857 thousand (YoY +126.7%) |
| Ordinary income | ¥102,558 thousand (YoY +23.2%) |
| Profit attributable to owners of the parent | ¥88,492 thousand (YoY +199.5%) |
| Total assets | ¥9,854,547 thousand |
| Net assets | ¥4,917,281 thousand |
| Cash flows from operating activities | ¥-591,477 thousand |
| Cash flows from investing activities | ¥-42,459 thousand |
| Cash flows from financing activities | ¥587,705 thousand |
| Cash and cash equivalents at end of period | ¥2,058,422 thousand |
| Revision to Earnings Forecast | None |
| Segment revenue | Drug Discovery Support Business ¥975,969 thousand (YoY +4.1%), Investment and consulting business ¥6,096,991 thousand (YoY +15.3%) |
| Segment profit | Drug Discovery Support Business ¥-48,569 thousand, Investment and consulting business ¥294,299 thousand (YoY +20.1%) |
| Depreciation and amortization | ¥50,115 thousand |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sale of property, plant and equipment ¥1,177 thousand / Extraordinary loss Loss on disposal of non-current assets ¥748 thousand, Business restructuring loss ¥7,123 thousand |
| Disclosure regarding the going concern assumption | Not applicable. |
| Material subsequent events | Following the closure of the Kobe Research Center, fixed assets including land and buildings will be transferred. The transfer price is ¥1,266.820 million, the book value is ¥912.112 million, and the gain on transfer is approximately ¥310 million. The gain is scheduled to be recognized as extraordinary income in the third quarter of the fiscal year ending March 2027. |
| Factors Behind Changes in Business Performance | In the Drug Discovery Support business, progress in contract testing and cost reductions through the streamlining of operations; in the Investment and Consulting business, improvements in the e-commerce market environment, completion of large-scale orders, demand capture, price pass-through and cost control. |
Items this document does not state (16)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.In the Drug Discovery Support business, contract testing progressed generally as planned, and costs were reduced through the streamlining of operations. In the Investment and Consulting business, improvements in the e-commerce market environment, completion of large-scale orders, demand capture, price pass-through and cost control contributed to higher revenue and higher profit.